Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Inventory (2024 - 2025)

Caris Life Sciences has reported Inventory over the past 2 years, most recently at $63.6 million for Q4 2025.

  • Quarterly results put Inventory at $63.6 million for Q4 2025, up 60.78% from a year ago — trailing twelve months through Dec 2025 was $63.6 million (up 60.78% YoY), and the annual figure for FY2025 was $63.6 million, up 60.78%.
  • Inventory for Q4 2025 was $63.6 million at Caris Life Sciences, up from $49.3 million in the prior quarter.
  • Over the last five years, Inventory for CAI hit a ceiling of $63.6 million in Q4 2025 and a floor of $39.6 million in Q4 2024.